Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$30.83
+2.1%
$28.56
$23.42
$62.58
$1.79B0.77682,804 shs531,184 shs
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
$12.95
+1.4%
$12.86
$7.75
$19.09
$1.73B1.53651,262 shs607,374 shs
PureTech Health plc stock logo
PRTC
PureTech Health
$17.80
-1.1%
$17.22
$13.30
$32.98
$427.54M1.144,681 shs3,874 shs
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$28.33
-3.7%
$35.90
$27.12
$60.90
$1.70B2.54974,854 shs1.14 million shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
+2.09%+2.39%+4.09%-10.29%-20.56%
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
+1.41%+1.01%-5.82%-14.01%+59.88%
PureTech Health plc stock logo
PRTC
PureTech Health
+2.21%-0.61%+3.96%-4.61%-40.67%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-3.67%-0.49%-29.00%-26.53%-33.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
3.985 of 5 stars
3.31.00.04.22.80.81.9
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
3.4594 of 5 stars
4.51.00.00.03.33.30.6
PureTech Health plc stock logo
PRTC
PureTech Health
2.5779 of 5 stars
3.85.00.00.02.80.00.0
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
4.2003 of 5 stars
4.41.00.04.43.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.56
Moderate Buy$56.0081.64% Upside
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
3.00
Buy$27.89115.36% Upside
PureTech Health plc stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00152.81% Upside
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4077.90% Upside

Current Analyst Ratings Breakdown

Latest PRTC, AGIO, CNTA, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
5/8/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform ➝ Outperform$6.00
5/8/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
5/2/2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.00
4/10/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$58.00 ➝ $45.00
3/31/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$38.00
3/28/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$37.04M48.21N/AN/A$27.02 per share1.14
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
$15M115.34N/AN/A$2.42 per share5.35
PureTech Health plc stock logo
PRTC
PureTech Health
$4.32M99.08N/AN/A$16.94 per share1.05
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$347.68M4.88N/AN/A$7.64 per share3.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$673.72M$11.242.72N/AN/A1,845.92%-2.51%-2.26%8/7/2025 (Estimated)
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
-$151.09M-$1.81N/AN/AN/AN/A-52.13%-38.01%8/12/2025 (Estimated)
PureTech Health plc stock logo
PRTC
PureTech Health
-$65.70MN/A0.00N/AN/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-59.76%-32.69%-25.25%8/1/2025 (Estimated)

Latest PRTC, AGIO, CNTA, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
-$0.35-$0.20+$0.15-$0.20N/AN/A
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
5/1/2025Q1 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million
3/24/2025Q4 2024
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
-$0.38-$0.34+$0.04-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
PureTech Health plc stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
11.90
11.56
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
0.15
21.52
21.52
PureTech Health plc stock logo
PRTC
PureTech Health
N/A
3.68
N/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
82.01%
PureTech Health plc stock logo
PRTC
PureTech Health
0.04%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39057.92 million54.47 millionOptionable
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
200133.60 million116.56 millionOptionable
PureTech Health plc stock logo
PRTC
PureTech Health
10024.02 million22.67 millionNot Optionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.92 million57.86 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$30.83 +0.63 (+2.09%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$31.53 +0.70 (+2.27%)
As of 05/28/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$12.95 +0.18 (+1.41%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$12.90 -0.05 (-0.39%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.80 -0.20 (-1.11%)
Closing price 05/28/2025 03:58 PM Eastern
Extended Trading
$18.38 +0.57 (+3.23%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$28.33 -1.08 (-3.67%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$28.76 +0.43 (+1.50%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.